BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18474295)

  • 1. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
    Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
    Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK; Levy R
    J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
    Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
    Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
    Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
    Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
    Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
    J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
    Lee JJ; Kim DH; Lee NY; Sohn SK; Kim JG; Kim HJ; Do YR; Park YH
    Br J Haematol; 2007 May; 137(4):329-36. PubMed ID: 17408400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].
    Zhang W; Wang X; Duan MH; Li J; Zhou DB
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):400-2. PubMed ID: 19567119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.
    Meyer zum Büschenfelde C; Feuerstacke Y; Götze KS; Scholze K; Peschel C
    Cancer Res; 2008 Jul; 68(13):5414-22. PubMed ID: 18593944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
    Gajra A; Vajpayee N; Grethlein SJ
    Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
    Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
    Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
    Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
    In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.